205 related articles for article (PubMed ID: 16249392)
1. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.
Rousseau RF; Biagi E; Dutour A; Yvon ES; Brown MP; Lin T; Mei Z; Grilley B; Popek E; Heslop HE; Gee AP; Krance RA; Popat U; Carrum G; Margolin JF; Brenner MK
Blood; 2006 Feb; 107(4):1332-41. PubMed ID: 16249392
[TBL] [Abstract][Full Text] [Related]
2. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.
Okur FV; Yvon E; Biagi E; Dotti G; Carrum G; Heslop H; Mims MP; Fratantoni JC; Peshwa MV; Li L; Brenner MK
Cytotherapy; 2011 Oct; 13(9):1128-39. PubMed ID: 21745159
[TBL] [Abstract][Full Text] [Related]
4. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures.
Cignetti A; Guarini A; Gillio Tos A; Reato G; Foa R
Cancer Gene Ther; 2000 Feb; 7(2):167-76. PubMed ID: 10770624
[TBL] [Abstract][Full Text] [Related]
6. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.
Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK
Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
8. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
9. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma.
Meziane el K; Bhattacharyya T; Armstrong AC; Qian C; Hawkins RE; Stern PL; Dermime S
Int J Cancer; 2004 Oct; 111(6):910-20. PubMed ID: 15300803
[TBL] [Abstract][Full Text] [Related]
10. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells.
Biagi E; Yvon E; Dotti G; Amrolia PJ; Takahashi S; Popat U; Marini F; Andreeff M; Brenner MK; Rousseau RF
Hum Gene Ther; 2003 Apr; 14(6):545-59. PubMed ID: 12718765
[TBL] [Abstract][Full Text] [Related]
11. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
12. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
[TBL] [Abstract][Full Text] [Related]
13. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.
Dotti G; Savoldo B; Takahashi S; Goltsova T; Brown M; Rill D; Rooney C; Brenner M
Exp Hematol; 2001 Aug; 29(8):952-61. PubMed ID: 11495701
[TBL] [Abstract][Full Text] [Related]
14. CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages.
Kennedy MK; Picha KS; Fanslow WC; Grabstein KH; Alderson MR; Clifford KN; Chin WA; Mohler KM
Eur J Immunol; 1996 Feb; 26(2):370-8. PubMed ID: 8617306
[TBL] [Abstract][Full Text] [Related]
15. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells.
Fujita N; Kagamu H; Yoshizawa H; Itoh K; Kuriyama H; Matsumoto N; Ishiguro T; Tanaka J; Suzuki E; Hamada H; Gejyo F
J Immunol; 2001 Nov; 167(10):5678-88. PubMed ID: 11698440
[TBL] [Abstract][Full Text] [Related]
16. CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells.
Prigozhina TB; Gurevitch O; Elkin G; Morecki S; Yakovlev E; Slavin S
Exp Hematol; 2003 Jan; 31(1):81-8. PubMed ID: 12543110
[TBL] [Abstract][Full Text] [Related]
17. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
[TBL] [Abstract][Full Text] [Related]
18. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
Biagi E; Rousseau R; Yvon E; Schwartz M; Dotti G; Foster A; Havlik-Cooper D; Grilley B; Gee A; Baker K; Carrum G; Rice L; Andreeff M; Popat U; Brenner M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6916-23. PubMed ID: 16203783
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes.
Thomas-Kaskel AK; Portugal TG; Herchenbach D; Houet L; Veelken H; Finke J
Acta Haematol; 2007; 117(4):226-35. PubMed ID: 17308369
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation.
Marijt E; Wafelman A; van der Hoorn M; van Bergen C; Bongaerts R; van Luxemburg-Heijs S; van den Muijsenberg J; Wolbers JO; van der Werff N; Willemze R; Falkenburg F
Haematologica; 2007 Jan; 92(1):72-80. PubMed ID: 17229638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
